Several clinical trials on the efficacy of BTZ in other hematological diseases, such as acute lymphoid and myeloid leukemia, indolent B-cell non-Hodgkin lymphoma and diffuse large B-cell lymphoma, are ongoing [21]. The gene discussed is CASC3; the disease is hematologic disorder.